Kristin Chidsey

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo et al. · Nature Medicine · 2021 · 134 citations

Metabolic Syndrome, Diabetes Management, Diabetes +5

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

Jemy A. Gutierrez, Wei Liu, Sylvie Perez et al. · Molecular Metabolism · 2021 · 80 citations · Full text

Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial

David J. Kazierad, Kristin Chidsey, Veena Somayaji et al. · Med · 2021 · 72 citations · Full text

Fatty Liver Disease, Randomized Phase 2, Obesity +16

Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

Neeta B. Amin, Santos Carvajal‐Gonzalez, Julie J. Purkal et al. · Science Translational Medicine · 2019 · 68 citations · Full text

Determination of receptor occupancy in the presence of mass dose: [¹¹C]GSK189254 PET imaging of histamine H₃ receptor occupancy by PF-03654746

Jean‐Dominique Gallezot, Beata Planeta, Nabeel Nabulsi et al. · Journal of Cerebral Blood Flow & Metabolism · 2016 · 65 citations · Full text